Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Preferred Stock Liabilities came in at $143.3 million in Q1 2026, up 1.22% on a QoQ basis from $141.5 million in Q4 2025.
Transcode Therapeutics (RNAZ) Preferred Stock Liabilities (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 4 years of Preferred Stock Liabilities data on file, last reported at $143.3 million in Q1 2026.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $143.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143.3 million (changed N/A YoY) and the FY2025 annual result came in at $141.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $143.3 million in Q1 2026, from $141.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $143.3 million in Q1 2026 to a low of $141.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 143.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.27 Mn |
| Dec 31, 2025 | 141.54 Mn |
| Jun 30, 2021 | 34,145.00 |
| Dec 31, 2020 | 1.75 Mn |